The American College of Rheumatology Adds the Vectra® Test to List of Recommended Disease Activity Measures for Rheumatoid A...
November 20 2019 - 7:05AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular
diagnostics and precision medicine, announced that the American
College of Rheumatology (ACR) has included the Vectra® test in its
list of recommended disease activity measures for patients with
rheumatoid arthritis (RA). The new recommendations were
published in the journal Arthritis Care & Research.
The publication titled “2019 Update of the American College of
Rheumatology Recommended Rheumatoid Arthritis Disease Activity
Measures” states that the Vectra test is among 11 disease activity
measures that met a minimum standard by categorizing into disease
activity states and being feasible for regular clinical use, and
that Vectra was one of the five most frequently studied RA disease
activity measures among 46 evaluated. Currently, there are
more than 35 peer-reviewed Vectra journal publications.
“We are excited that the Vectra test has been included the ACR’s
recommendations for disease activity measures. It will provide
physicians with an additional option to evaluate their patients
with RA,” said Elena Hitraya, M.D., Ph.D., chief medical officer,
Myriad Autoimmune. “Vectra objectively measures the
inflammation associated with RA and can provide valuable
information to help clinicians improve treatment decisions and
outcomes for patients with RA.”
Three out of four rheumatologists have used Vectra and have
ordered more than 900,000 tests for their patients. RA is an
autoimmune disease that attacks the patient’s joints and often
affects other organ systems, leading to significant morbidity,
increased mortality and financial burden. Approximately 60
percent of people with inadequately treated RA are unable to work
by a decade after its onset. The American College of
Rheumatology estimates that RA affects 1.5 million people in the
United States.
About Vectra®Vectra is a
multi-biomarker molecular blood test that provides an objective and
personalized measure of inflammatory disease activity in patients
with rheumatoid arthritis. Vectra provides unsurpassed ability to
predict radiographic progression and can help guide medical
management decisions with the goal of improving patient outcomes.
Vectra testing is performed at a state-of-the-art CLIA (Clinical
Laboratory Improvement Amendments) facility. Test results are
reported to the physician five to seven days from shipping of the
specimen. Physicians can receive test results by fax or the private
web portal, VectraView. For more information on Vectra, please
visit: www.vectrascore.com.
About Myriad
GeneticsMyriad Genetics Inc. is a leading precision
medicine company dedicated to being a trusted advisor transforming
patient lives worldwide with pioneering molecular
diagnostics. Myriad discovers and commercializes molecular
diagnostic tests that: determine the risk of developing disease,
accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
five critical success factors: building upon a solid
hereditary cancer foundation, growing new product volume, expanding
reimbursement coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate
2020. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris,
Foresight and Prequel are trademarks or registered trademarks of
Myriad Genetics, Inc. or its wholly owned subsidiaries in the
United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor StatementThis press release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to improving clinician treatment decisions and
outcomes for patients with RA; and the Company's strategic
directives under the caption "About Myriad Genetics." These
"forward-looking statements" are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by
forward-looking statements. These risks and uncertainties
include, but are not limited to: the risk that sales and profit
margins of our molecular diagnostic tests and pharmaceutical and
clinical services may decline; risks related to our ability to
transition from our existing product portfolio to our new tests,
including unexpected costs and delays; risks related to decisions
or changes in governmental or private insurers’ reimbursement
levels for our tests or our ability to obtain reimbursement for our
new tests at comparable levels to our existing tests; risks related
to increased competition and the development of new competing tests
and services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services and any future tests and services are terminated
or cannot be maintained on satisfactory terms; risks related to
delays or other problems with operating our laboratory testing
facilities and our healthcare clinic; risks related to public
concern over genetic testing in general or our tests in particular;
risks related to regulatory requirements or enforcement in the
United States and foreign countries and changes in the structure of
the healthcare system or healthcare payment systems; risks related
to our ability to obtain new corporate collaborations or licenses
and acquire new technologies or businesses on satisfactory terms,
if at all; risks related to our ability to successfully integrate
and derive benefits from any technologies or businesses that we
license or acquire; risks related to our projections about our
business, results of operations and financial condition; risks
related to the potential market opportunity for our products and
services; the risk that we or our licensors may be unable to
protect or that third parties will infringe the proprietary
technologies underlying our tests; the risk of patent-infringement
claims or challenges to the validity of our patents or other
intellectual property; risks related to changes in intellectual
property laws covering our molecular diagnostic tests and
pharmaceutical and clinical services and patents or enforcement in
the United States and foreign countries, such as the Supreme Court
decision in the lawsuit brought against us by the Association for
Molecular Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; the risk that we may be unable to comply with
financial operating covenants under our credit or lending
agreements; the risk that we will be unable to pay, when due,
amounts due under our credit or lending agreements; and other
factors discussed under the heading "Risk Factors" contained in
Item 1A of our most recent Annual Report on Form 10-K for the
fiscal year ended June 30, 2019, which has been filed with the
Securities and Exchange Commission, as well as any updates to those
risk factors filed from time to time in our Quarterly Reports on
Form 10-Q or Current Reports on Form 8-K. All information in
this press release is as of the date of the release, and Myriad
undertakes no duty to update this information unless required by
law.
Media
Contact: |
Ron
Rogers |
|
Investor
Contact: |
Scott
Gleason |
|
(801) 584-3065 |
|
|
(801) 584-1143 |
|
rrogers@myriad.com |
|
|
sgleason@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024